Project Grant R21AI193496
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$159K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel and effective medical countermeasure to treat gastrointestinal acute radiation syndrome (GI-ARS) in individuals exposed to high doses of ionizing radiation. The $167,500 award to The Feinstein Institutes for Medical Research, a non-profit medical research organization, will fund research to determine the mechanism of...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $157,500.00 to the University of California, Los Angeles (UCLA) to develop and test new radiation mitigator compounds based on the estrogen receptor beta (ER-beta) agonist DPN. The goal is to create orally bioavailable DPN analogues that can more effectively treat bone marrow, gastrointestinal, respiratory, and cardiovascular injuries caused by total-body...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) seeks to develop novel mitigators of gastrointestinal acute radiation syndrome (GI-ARS) by targeting the STING-clusterin (CLU) axis to promote regeneration of irradiated intestinal epithelium. The total award amount is $515,326, with a project period from December 2, 2024 to November 30, 2029. Key objectives include defining the mechanisms by which CLU...
This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $158,500.00 to Trustees of Indiana University, doing business as Indiana University Indianapolis, to develop a novel non-pharmacological strategy to mitigate radiation-induced cardiotoxicity. The research aims to determine optimal parameters for a "protective wounding" approach, where a small subcutaneous incision after radiation exposure can...
This Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) is focused on evaluating the efficacy of the natural compound apigenin as a potential therapeutic countermeasure against gastrointestinal acute radiation syndrome (GI-ARS) in mice. The $158,500 award, effective July 22, 2025 through June 30, 2027, will support research to determine the most effective route of apigenin administration for counteracting radiation-induced intestinal...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to SRI International provides $401,125 in funding to quantify the association between genetic factors and radiation sensitivity in cancer patients. The research aims to identify germline genetic variants and gene expression patterns that contribute to individual differences in radiation response. The goal is to develop a predictive screening platform to optimize radiation dosing and mitigate...
The National Institutes of Health (NIH) awarded a $239,363 Project Grant under the Research Infrastructure Programs (CFDA 93.351) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. The grant aims to determine the radioprotective efficacy of dietary administration of highly radiation-resistant non-pathogenic fungi in the Drosophila model system. The research will evaluate if consumption of these fungal strains can increase resistance to acute radiation damage across...
The University of Iowa was awarded a $1,354,009 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant, which runs from September 1, 2024 to August 31, 2027, aims to develop clinically deliverable RNA strategies for radiation protection. Specifically, the project will leverage the protective qualities of extremophile proteins and new delivery methods to reduce the impact of radiation-induced injuries...
This U01 Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the mechanism by which the hormone ghrelin confers radioprotection to the gastrointestinal (GI) system and to preclinically develop human ghrelin as a safe and effective mitigator for GI acute radiation syndrome (GI-ARS). The total funding amount is $586,240 over the period of December 5, 2024 to November 30, 2029. The research will be...
This $462,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to establish the epigenetic mechanisms that govern embryonic stem cell (ESC) biology. The research aims to define how ESC gene expression programs and biology are regulated by DNA methylation and the TET family of DNA demethylases. Key objectives include: Dissecting the molecular and biological requirements...